Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
about
Update in Cystic Fibrosis 2014Bronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisOrganisms isolated from adults with cystic fibrosisTreatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisThe Evolution of Cystic Fibrosis CareThe structural biology of phenazine biosynthesisExhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosisStandard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosisInitial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosisIdentification of DNA markers for a transmissible Pseudomonas aeruginosa cystic fibrosis strain.A laminar flow model of aerosol survival of epidemic and non-epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis.Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis.2-Aminoacetophenone as a potential breath biomarker for Pseudomonas aeruginosa in the cystic fibrosis lung.Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Influenza-associated cystic fibrosis pulmonary exacerbations.The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes.Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosisAdherence with tobramycin inhaled solution and health care utilization.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentThe changing microbial epidemiology in cystic fibrosis.Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis.Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis.The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention.Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients.Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomesComparison of three molecular techniques for typing Pseudomonas aeruginosa isolates in sputum samples from patients with cystic fibrosisClinical significance of microbial infection and adaptation in cystic fibrosis.Therapy with macrolides in patients with cystic fibrosis.Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung diseaseThe rationale for aerosolized antibiotics.Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.
P2860
Q22306307-7A42F7D8-EEAD-4E97-9FC3-CD9D64E5298DQ24186413-B32A73D0-CEBF-4B6A-A14D-71BF862D30F8Q24188054-38B81B0F-3428-43F1-A9DC-8FEA5C3C873CQ24201620-44AFD9FD-4CFA-4490-898D-8134FAFB38A3Q24202879-EE43DB8D-377D-4EE3-A512-B1238F4CD6DCQ24234964-2E38E25E-40F5-40FE-8F09-74D869354D37Q24240388-62AC6CF8-0D4F-458D-A754-603BC4AD31DBQ24243916-B11EF70D-7D5E-4F3C-BD1B-26A820CF5420Q24801361-9CF488B7-29F2-4B5D-AC22-D4073355516BQ26470661-7C99B1E7-E4E1-417A-BA3F-5AC787A75AF3Q26471106-67140B37-A5B8-41D7-B560-49078E893E9AQ26829604-A8DFEC0E-B869-44B9-B106-E46A6E0EBD2BQ26999299-985FA4A9-5F99-487A-9062-3F3E51094D5FQ27021934-7D664BD0-F3A4-4272-8A47-A23D097BC28CQ28596799-AEFEFD22-CBE8-49CA-BC17-91459047A2F1Q30412485-E7F5817E-59A7-4D0A-AA97-48AFECFD3D7AQ30422695-CDBF0722-881E-4327-AAE2-AE22166C1817Q33214091-F0D7D09B-755F-4108-84EC-E6DD6206F1A7Q33346997-97DF50D6-AA25-4BB4-8B8C-584ED6B62841Q33592546-6EEDEB35-C265-4D58-ADC2-BFC5CEF98372Q33740049-1ED9B940-17B8-43D8-8296-71660451E9ACQ33755342-759681DA-2EF2-4BBB-BA20-FC3278A81D26Q33776832-324998CA-12A4-4005-9B41-E40A82555464Q33780971-8062520C-27F2-448D-B110-8EAA2687BFA8Q33785116-D69C0C15-A7FC-4BE5-B750-BA00785AA6ABQ33798682-0CC6B079-E69F-445B-A56A-46B71259A0C1Q33824149-6CA26637-36F3-4561-9AA1-D9A962B2CEA5Q33825634-BD1115B2-2B04-4202-B328-94486822F1ECQ33869527-61D5F9DE-7DEA-4862-B809-8B6EF592C818Q33956730-1FB90D8B-EB8E-4E9C-A7C9-5872354C472DQ33960112-91D47324-1845-428E-B89F-402BF097AC80Q34016539-0F42845B-4BDF-4E1B-8B81-ED78C575DE1AQ34243590-5DAD6A31-C732-4A1E-BEAD-28F2D3EC1B7CQ34480377-97552632-DFD5-48CB-93D0-58FE9EB1D2DFQ34487493-FB815D06-81B0-4F5F-842C-C6954D7050CDQ34491552-C75344D0-DDED-41CB-8E2C-424CE88045FFQ34523880-9A7DFECF-8912-4E68-8E6D-E1159441DA57Q34554550-05435DCF-F04D-4923-A8E4-3F3C77A2F887Q34566912-2C386EF8-71CF-4144-B617-8EC8055082B3Q34956792-10D923D9-0509-4D0F-BC3D-3A181067C04C
P2860
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@en
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@nl
type
label
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@en
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@nl
prefLabel
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@en
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
@nl
P2093
P356
P1476
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
@en
P2093
Armstrong DS
Grimwood K
Robertson CF
P304
P356
10.1067/MPD.2001.112897
P407
P577
2001-05-01T00:00:00Z